Gold therapy carries with it a risk of a life threatening toxic reaction."l' Blood dyscrasias, especially thrombocytopenia, are not uncommon. Gold induced thrombocytopenia is alarming: it is frequently sudden, severe, and unpredictable but may occur more gradually and does not appear to be dose related.5 The mechanism of thrombocytopenia remains uncertain but may be due to direct marrow suppression or to specific antiplatelet antibody production. An association with the class II B cell isoantigen HLA-DR3 and with the class I antigen HLA-B8 has previously been found in patients with a profound thrombocytopenia. 6 In order to determine whether this marker can help in predicting all those at risk of developing a thrombocytopenia the clinical features and outcome of 17 (2) Alternatively, GST may act as a hapten bound to a plasma protein macromolecule, which then acts as the immunogen, the platelets being innocent bystanders which non-specifically adsorb the resulting immune complexes. It has been shown that the HLA-DR3 phenotype is associated with delayed Fc receptor mediated clearance of IgG sensitised autologous erythrocytes.13 GST accumu- lates in the mononuclear-phagocyte system'4 and might therefore enhance this effect.
The HLA-B8, DR3 phenotype is strongly associated with autoimmune diseases. The aberrant expression of class II major histocompatibility antigens by several cell lines is established""'8 and is one postulated mechanism for the development of autoimmune phenomena.19 The finding in the present study that all group I patients are HLA-DR3 positive raises the possibility that exposure to gold may result in the aberrant expression of this antigen on the megakaryocyte or earlier progenitor cell.
The features observed in the second group with a more gradual onset of thrombocytopenia and absent antiplatelet antibodies are not so readily explained. The clinical findings are more in keeping with a direct selective suppression of thrombopoiesis. Both marrow aplasia and granulocytopenia due to GST are recognised.5 GST in vitro inhibits the formation of granulocyte macrophage colonies in a dose dependent manner in concentrations that are achieved in vivo,2 but the exact mechanism by which gold compounds induce cellular toxicity is not known. The interaction of GST with sulphydryl groups is one postulated mechanism of gold toxicity2' and of its therapeutic effect.22 It is therefore of interest that four group II patients have group.bmj.com on October 1, 2017 -Published by http://ard.bmj.com/ Downloaded from also developed a thrombocytopenia on penicillamine, another thiol containing compound.
The strong association in group I with the presence of HLA-DR3 raises the question whether GST should be withheld in DR3 positive patients. Prospective studies to determine the risk of toxicity in this subset have been suggested, but this approach would represent a considerable financial undertaking.23 Approximately 26% of patients with RA possess HLA-DR3, and the highest estimated incidence of GST thrombocytopenia is 8% (more commonly around 3%). In our study 60% of patients with thrombocytopenia belonged to group I, therefore less than 5% (probably less than 2%) of gold treated patients are liable to develop a sudden, precipitous thrombocytopenia. If prior HLA typing dictated choice of therapy, four out of five DR3 positive patients would be unnecessarily denied the potential benefits of GST therapy. At present the HLA association with gold induced thrombocytopenia is more of theoretical than practical interest.
